BNET Industries
Vertex Pharmaceuticals Inc. (VRTX) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $199.0M
- Profit
- Dec 31 2007
- ($391.2M)
- Market Cap
- Sep 03 2008
- $3.7B
Latest News and Analysis
Nasdaq 100 Struggles
Hickey and Walters Bespoke submit: The tech-heavy Nasdaq 100 is currently set to have its third straight -1% decline. Below we highlight the 25 (out of 100) worst performing stocks in the index since last Thursday's close. As shown, Dell has lost nearly a fifth of its value...
5 Potential Buyout Targets in Biotech - Barron's
Bristol-Myers Squibb BMY made a $4.5B bid for the shares of ImClone IMCL it doesn't already own. Roche Holdings (RHHBY.PK) made a $44B offer for the shares of Genetech DNA it doesn't own. Both targets want the bid prices raised. Barron's Lawrence Strauss says these are just the two latest...
Vertex Pharmaceuticals Q1 2008 Earnings Call Transcript
Vertex Pharmaceuticals Q1 2008 Earnings Call Transcript
Vertex Pharmaceuticals Inc. Q4 2007 Earnings Call Transcript
Vertex Pharmaceuticals Inc. Q4 2007 Earnings Call Transcript
Vertex Pharmaceuticals Inc. Q3 2007 Earnings Call Transcript
Vertex Pharmaceuticals Inc. Q3 2007 Earnings Call Transcript
Vertex Pharmaceuticals Q2 2007 Earnings Call Transcript
Vertex Pharmaceuticals Q2 2007 Earnings Call Transcript
Vertex Pharmaceuticals Q1 2007 Earnings Call Transcript
Vertex Pharmaceuticals Q1 2007 Earnings Call Transcript
Vertex Pharmaceuticals Q4 2006 Earnings Call Transcript
Vertex Pharmaceuticals Q4 2006 Earnings Call Transcript
Vertex Pharmaceuticals Q3 2006 Earnings Call Transcript
Vertex Pharmaceuticals Q3 2006 Earnings Call Transcript
Vertex Pharmaceuticals Q2 2006 Earnings Conference Call Transcript (VRTX)
Vertex Pharmaceuticals Q2 2006 Earnings Conference Call Transcript VRTX
Vertex Pharmaceuticals Incorporated Q1 2006 Earnings Results Conference Call Transcript (VRTX)
Vertex Pharmaceuticals Incorporated Q1 2006 Earnings Results Conference Call Transcript VRTX
Vertex Pharmaceuticals Incorporated Q4 2005 Earnings Conference Call Transcript (VRTX)
Vertex Pharmaceuticals Incorporated Q4 2005 Earnings Conference Call Transcript VRTX
Additional Resources
Vertex Pharmaceuticals to Start Phase 3 'REALIZE' Trial with Telaprevir in Treatment-Failure HCV Patients
First HCV protease inhibitor in pivotal trial for this difficult to treat patient population Trial to enroll all major treatment-failure patient groups, including null responders, partial responders and relapsers Two telaprevir registration programs to address significant unmet need in treatment-naove and treatment-failure patients CAMBRIDGE,...
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2008 BMO Capital Markets Focus on Healthcare Conference
CAMBRIDGE, Mass. -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 BMO Capital Markets Focus on Healthcare Conference on Wednesday, August 6, 2008 at 9:00 a.m. EDT. The presentation will be webcast live and may be accessed from 'Events...
ONN Sidewinder Video Report: Wachovia Corporation Sees High Option Volume
The Monday, Aug 4, 2008 Sidewinder Video Report CHICAGO -- The Sidewinder Report, the www.onn.tv daily options news program recorded live on the floor of the Chicago Board Options Exchange, today examined options trading in the following securities: Wachovia Corporation WB Market Vectors Gold...
BellwetherReport.com Analyst Report on DRIV, THQI, ARRS and VRTX
BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...
Vertex Pharmaceuticals Highlights Telaprevir Progress and Reports Second Quarter 2008 Results
* Treatment-failure data and treatment-naove data strengthen telaprevir's potential profile and highlight broad opportunity in treatment of chronic hepatitis C virus HCV infection * VX-770, for cystic fibrosis CF, completes enrollment for 28-day Phase 2a study; 2009 targeted for initiation of registration studies, pending 28-day study results ...
Research and Markets: A Performance Analysis of Johnson & Johnson in the Ethical Pharmaceutical Sector: Including a Six Year Sales Forecast and Competitor Profiling
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/a3817c/johnson_johnson) has announced the addition of the "Johnson & Johnson: PharmaVitae Profile" company profile to their offering. This analysis examines the historical and forecast performance for J&J in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio...
Biotech Remains Upbeat in Wake of Market Turmoil, Burrill Analysis Finds
SAN FRANCISCO -- The biotech industry's report card for the first half of the year contains surprisingly good grades for its performance on the capital markets, and for partnering and venture capital deal making, but all other forms of financing didn't fare as well, particularly IPOs, the...
SAS® for Clinical Data Integration Helps Reduce Time-to-Market for New Drugs
SAS Streamlines Data Integration to Eradicate Errors and Manual Work That Delay Bringing Novel Therapies to Market CARY, NC -- SAS, the leader in business intelligence, today announced a new solution to help pharmaceutical companies deal with the ever growing volumes of health-related research information....
- Next »
- page 1 of 1
- « Previous
Sort byClose
View by Content TypeClose
- Incorporated: 1989
- CEO: Dr. Joshua S. Boger Ph.D.
- Employees: 1,132
Vertex Pharmaceuticals is engaged in discovering, developing, and commercializing small molecule drugs for the treatment of serious diseases, including human immunodeficiency virus infection, chronic hepatitis C virus (HCV) infection, cancer and bacterial infection. At Dec 31 2007, Co. concentrated most of its drug development resources on four drug candidates: telaprevir (VX-950) for the treatment of HCV infection, VX-702 for the treatment of rheumatoid arthritis and other inflammatory diseases, VX-770 for the treatment of cystic fibrosis and VX-883 for the treatment of bacterial infection. Co.'s pipeline also includes several drug candidates that are being developed by its collaborators.
Key Competitors
Vertex Pharmaceuticals Inc. Company Info
Board of Directors
Dr. Charles A. Sanders
Chairman
Dr. Stuart J.M. Collinson Ph.D.
Ms. Eugene H. Cordes Ph.D.
Mr. Matthew W. Emmens
Mr. Eric K. Brandt
Dr. Roger W. Brimblecombe Ph.D.
Mr. Bruce I. Sachs
Dr. Joshua S. Boger Ph.D.
Ms. Elaine S. Ullian
Contact Information
130 Waverly Street
Cambridge, MA
617 444-6100